Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- apoptóza účinky léků genetika MeSH
- buněčný cyklus účinky léků genetika MeSH
- Kaplanův-Meierův odhad MeSH
- kolorektální nádory farmakoterapie genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA antagonisté a inhibitory genetika metabolismus MeSH
- nádorové buněčné linie MeSH
- nádory tračníku genetika patologie MeSH
- pohyb buněk účinky léků genetika MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- viabilita buněk účinky léků genetika MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- mikro RNA MeSH
- MIRN21 microRNA, human MeSH Prohlížeč
- protinádorové látky MeSH
PURPOSE: MicroRNA-21 (miR-21) is one of the miRNAs that are frequently and highly overexpressed in tumor tissue of colorectal cancer (CRC) patients; however, only a little is known about its functional role in CRC. METHODS: We examined the expression level of miR-21 in 44 paired samples of tumoral and non-tumoral colon tissues diagnosed for CRC using TaqMan real-time PCR method. Furthermore, we used miR-21 inhibitor (anti-miR-21) to transient knockdown of miR-21 in DLD-1 colon cancer cells and examined the effects of miR-21 silencing on viability, apoptosis, chemosensitivity, cell cycle, and migration of DLD1 cells. RESULTS: The expression levels of miR-21 were significantly increased in CRC tumor tissue (P < 0.0001). Significant differences in miR-21 levels were observed also between CRC tissues of patients with CRC in different clinical stages: I vs. II (P = 0.033) and I vs. IV (P = 0.021). Kaplan-Meier analysis proved that the miR-21 expression levels are correlated to shorter overall survival of CRC patients (P = 0.0341). MiR-21 silencing in DLD1 cell line had no effect on the cell viability; however, when combined with chemotherapeutics (5-FU, L-OHP, and SN38), it contributed to the decrease of cell viability. Suppression of miR-21 decreased cell migration ability of DLD-1 cells by nearly 30 % (P = 0.016). CONCLUSION: We have confirmed the overexpression of miR-21 in CRC samples and its correlation with advanced disease and shorter overall survival. These findings could be described in part by the fact that CRC cells with increased expression of miR-21 have higher migration ability.
Zobrazit více v PubMed
Mol Cancer. 2009 Nov 14;8:102 PubMed
Lab Invest. 2008 Dec;88(12):1358-66 PubMed
Mol Cancer. 2007 Sep 25;6:60 PubMed
FEBS Lett. 2011 Oct 3;585(19):2998-3005 PubMed
Int J Colorectal Dis. 2011 Nov;26(11):1415-22 PubMed
Breast Cancer Res. 2011 Jan 10;13(1):R2 PubMed
Methods Mol Biol. 2011;744:145-57 PubMed
JAMA. 2008 Jan 30;299(4):425-36 PubMed
Cell. 2000 Jan 7;100(1):57-70 PubMed
J Biol Chem. 2007 May 11;282(19):14328-36 PubMed
BMB Rep. 2009 Sep 30;42(9):593-8 PubMed
Cancer Res. 2008 Oct 1;68(19):8164-72 PubMed
Int J Gynecol Cancer. 2011 Jan;21(1):8-14 PubMed
Hepatology. 2009 May;49(5):1595-601 PubMed
RNA. 2008 Nov;14(11):2348-60 PubMed
Oncology. 2007;72(5-6):397-402 PubMed
Med Oncol. 2011 Dec;28(4):1469-74 PubMed
Cell Res. 2009 Jul;19(7):828-37 PubMed
J Biol Chem. 2010 Jun 25;285(26):20281-90 PubMed
Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 PubMed
Arch Med Res. 2011 May;42(4):281-90 PubMed
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21098-103 PubMed
Cancer Sci. 2011 Dec;102(12):2186-90 PubMed
BMC Biotechnol. 2010 Jun 23;10:47 PubMed
